An important corollary that can be derived from our analysis is that people with T2DM on EECP therapy for angina due to CAD need to reduce the dose of their antidiabetes medication (oral antidiabetes medications and/or insulin) to prevent the risks of hypoglycaemia during and up until at least 12 weeks after EECP therapy completion. Here, INS is linked to angina pectoris.